A 70-years-old strong smoker (50 pack years) was referred to our center due to increasing dyspnea, coughing and hemoptysis. The patient was in reduced general clinical conditions. The contrast-enhanced tomography revealed huge tumor mass of the right bronchial system (Figure 1). The staging procedure showed multiple osseous, hepatic and lymphatical metastasis. There were no surgical options; a systemic palliative therapy was to be initiated after the histological and immunhistological examination. AbstractWe were able to recanalize the major lumen of the right main bronchial branch, which was completely blocked because of huge tumor mass from the right upper lobe. With the cryo-therapy, we could freeze and remove the major portion of this huge tumor mass.

No abstract

The A 43-year-old nonsmoking woman was referred to our center due to increased dyspnea and hemoptysis. She was in reduced functional status (ECOG I). Contrast-enhanced-CT-scan revealed a tumor mass in the left lower lobe (Figure 1a). Histology revealed a non-small cell lung AbstractWe The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. Nivolumab received FDA approval for the treatment of melanoma in December 2014. On 24 April 2015, the Committee for Medical Products for Human Use of the European Medicine Agency recommended approval of Nivolumab for metastatic melanoma as a monotherapy. In March 2015, the US FDA approved it for the treatment of squamous non-small cell lung cancer.This case reports about a patient with metastatical pulmonary adenocarcinoma who benefited from the therapy with nivolumab. Already after 10 weeks of treatment with nivolumab, we registered rapid tumor remission.carcinoma, pulmonary adenocarcinoma, and further immunological evaluation revealed no mutations of EGFR or rearrangements of the anaplastic lymphoma kinase ALK.The staging-procedure revealed osseous and cerebral metastasis. Therefore, a combined therapy consisting of palliative chemotherapy with carboplatin and vinorelbine, palliative radiation of osseous and cerebral metastasis was also initiated. Due to reduced renal function, pemetrexed was not feasible.After 2 cycles of carboplatin and vinorelbine, thoracic CT-scan revealed tumor progression (Figure 1b).We initiated second-line therapy with nivolumab. The weight related dosage of nivolumab was between 180 mg and 190 mg. Within 10 weeks after 5 cycles of nivolumab, the reevaluation revealed significant pulmonary tumor remission (Figure 2a and 2b).

No abstract

No abstract